About
Amphista Therapeutics develops precision medicines using proprietary Targeted Glues™ technology to degrade disease-causing proteins by leveraging novel E3 ligases, focusing on high-value therapeutic targets such as acute myeloid leukemia.
Explore Amphista Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.